Join
Live feed
·
PRReleasevia Quantisnow
Viking Therapeutics Inc. logo

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

ByQuantisnow·Wall Street's wire, on your screen.
VKTX· Viking Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VKTX (Viking Therapeutics Inc.) and more on Quantisnow.